Audit: QRS - Young Plasma Transfusion for Health & Longevity
Audit conducted on 22/09/2026 20:00 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 83 |
| Failed | 0 |
| N/A | 11 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells trace to ER lines 351–355; time-to-effect cells to ER lines 384 and 408; benefits/risks to the ER tier headings; at-a-glance to ER Conclusion lines 485–491. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Laboratory measures only; no recovery benefit shown” mirrors ER line 155; “Harms are well characterized” mirrors ER line 489. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | All contraindication thresholds and time windows carried at ER strength; ACE inhibitors retained as a contraindication, not downgraded to a caution. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER “Populations who should avoid” list plus the ER’s explicit absolute contraindication; interactions from the ER interaction bullets. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No citations, PMIDs, NCT IDs or expert names appear; drug names in the gates are the ER’s own generic-name examples. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, sceptical register matches the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Thresholds and targets are given plainly without alarm or advocacy. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as evidence and reference values, not instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives directed at a reader; monitoring cadence is descriptive of the ER protocol. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No recommending or advising verbs used. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the rendered content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Immunoglobulin, apheresis and clock terms are unavoidable and match the ER; at-a-glance is jargon-free. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit and risk item is reduced to the bare fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framed for elective, self-directed use, consistent with the ER’s framing. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Retains cost/invasiveness and full apheresis monitoring schedule without simplification. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes access to laboratory panels and a specialist procedure. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance foregrounds the removal-versus-addition distinction that matters for an elective purchaser. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “marketed for longevity”; the term “anti-aging” does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route is given as “infusing”, “infusion”, “exchange” and “apheresis”; the one informal phrase (“drugs that ride on plasma proteins”) is the ER’s own bold label reproduced verbatim per 4.2. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present unchanged at lines 440, 477, 519, 539, 556, 576, 595, 599–601, 736 and in the tier list items. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; marker_#* and qualitative_item# expanded to 11 and 6 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes confined to the metadata block and the variable spans; the three website= spans and all CSS are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels and all eight interaction labels reproduce the ER bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels are drawn from the ER’s own phrasing at lines 384 and 408. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s ⚠️ Conflicted markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is reduced to minimal ER-derived phrasing; the remaining volume is driven by items 8.2, 9.2, 14.2 and 15.2, which mandate the full gate, biomarker and qualitative lists. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: young_plasma_transfusion_2026-0815-0808_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.22, matching QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0922-1949. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” carries no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual filename on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Young Plasma Transfusion for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417, correctly entity-encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/22/2026” from 2026-0922-1949. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” list was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “is a procedure infusing the liquid part of blood from young donors into older adults, marketed for longevity” before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs (ER lines 485–491). |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 69 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Small trials in dementia/Parkinson’s → line 485; removal beats addition → line 487; harms well characterized → line 489; expensive/invasive/uninsured → line 491. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; plasma is glossed as “the liquid part of blood”. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial named. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric results present. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER lines 301 and 315–325. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All nine “populations who should avoid” entries plus the ACE-inhibitor absolute contraindication are present. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Ten <li> elements, lines 542–551. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationales (“in whom no safety data exist”, “in whom alloimmunization can prolong waiting time”, “mirroring the exclusion criteria applied in every trial”) all stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | 7 mg/dL, NYHA III–IV, EF below 30%, 90 days, CKD stage 4, eGFR below 30, fibrinogen below 1.5 g/L, 5 years and the 24-hour window are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER lines 297–313. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight non-contraindication interaction bullets present; ACE inhibitors correctly excluded and placed in the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements, lines 559–566. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s em-dash glosses (“— blood thinners”, “— laboratory-made antibody drugs”) and all mechanistic rationale are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example-drug list is carried through intact. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from ER Therapeutic Protocol lines 351–355. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The ER’s three named approaches — whole plasma infusion, plasma exchange with albumin, plasma protein fractions — are the ER’s own top-level protocol bullets. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells carry ER-sourced dosing, schedule and donor-age detail. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The three components of the ER’s own “Time to effect” bullet (line 408), with the durability note corroborated at line 384. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Clock-based change (ER Medium tier) first, protein/immune signalling (ER Low tier) second, loss of effect last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells carry ER-sourced timing and qualification. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect information at line 408. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from ER lines 143–185. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 521–532. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER benefit heading alone; the ⚠️ Conflicted markers, magnitudes and sponsor attributions are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content remains in any benefit entry. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier benefit; line 521 sets style="display: none" with no empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from ER lines 209–277. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 578–589. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER risk heading alone; per-unit rates and the ⚠️ Conflicted marker are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content remains in any risk entry. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success table, lines 438–450. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 11 ER biomarker rows are reproduced with their optimal ranges and rationales intact. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 730 reproduces the ER’s schedule from line 436 (pre-exchange draws, 4 weeks, 3 months, 6-monthly, serology at 3 and 6 months). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER qualitative-marker list, lines 454–459. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present verbatim at lines 739–754. |
Issues 22/09/2026 20:00
Pass rate 100.00%. No issues found.
Issues 22/09/2026 19:51
- 11.4 — Time-to-effect subs duplicate values:
time_1_sub(“Measurable at one to two months”, line 489) andtime_2_sub(“Appear within days of infusion”, line 500) are word-for-word restatements oftime_1_valueandtime_2_value, so two of the six Time-to-effect cells carry no information.
Fixes 22/09/2026 19:51
- 11.4 — Time-to-effect subs duplicate values: Replaced
time_1_sub“Measurable at one to two months” with “Composite biological age fell after plasma exchange” andtime_2_sub“Appear within days of infusion” with “Laboratory measures only; no recovery benefit shown”, so both cells add ER-supported information instead of restating their value.